Guardant Health, Inc.

Guardant Health, Inc. is a precision oncology company that provides blood and tissue tests, as well as data sets, in the United States and globally. Its main products include the Guardant360 CDx test, a liquid biopsy for tumor mutation profiling; the Guardant360 Liquid test, which measures over 740 genes and supports all guideline-recommended biomarkers; the Guardant Reveal blood test that detects cancer at the molecular level using circulating tumor DNA; and the Guardant360 Tissue test for molecular profiling of tumor tissue. The company also offers the Shield blood test for colorectal cancer screening in adults, the GuardantINFINITY test for cancer research and therapy development, and the GuardantOMNI test covering 500 genes. Additionally, Guardant provides data and software solutions like GuardantINFORM, GuardantConnect, and the Smart Platform for multiomic insights.

Guardant Health, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol GH. Its shares are traded in United States Dollars (USD). The company is headquartered in the United States and operates primarily in the US and globally, with a focus on the healthcare sector.

Guardant Health operates in the Healthcare sector and is specifically classified under the Diagnostics & Research industry. This means the company is involved in developing and providing diagnostic tests and research tools, particularly for oncology. Its focus is on precision medicine, using advanced genomic, epigenomic, and RNA-based technologies to detect and monitor cancer. The company's products are used by healthcare providers, researchers, and biopharmaceutical customers to guide treatment decisions and advance cancer research.

Guardant Health's portfolio includes several key products. The Guardant360 CDx is a liquid biopsy test for tumor mutation profiling. The Guardant360 Liquid test measures over 740 genes and supports all guideline-recommended biomarkers. The Guardant Reveal is a blood test that uses circulating tumor DNA to detect cancer at the molecular level. The Guardant360 Tissue test provides genomic, transcriptomic, and epigenomic insights from tumor tissue. The Shield blood test is used for colorectal cancer screening in adults. For research, the GuardantINFINITY test offers insights into tumor molecular profiles and immune response, while the GuardantOMNI test covers 500 genes including those for homologous recombination repair deficiency and immuno-oncology. The company also offers data and software solutions like GuardantINFORM, GuardantConnect, and the Smart Platform.

Guardant Health, Inc. serves the United States and global markets. The company is based in the United States and its products are available both domestically and internationally. While the description summary does not specify particular countries outside the US, it states that the company operates 'globally.' Its tests and data solutions are used by healthcare providers, researchers, and biopharmaceutical customers worldwide to advance precision oncology and improve cancer detection and treatment.